Kezar Life Sciences Q2 Earnings Exceed Expectations, Cash Reserves Down
ByAinvest
Wednesday, Aug 13, 2025 4:37 pm ET1min read
KZR--
The company's cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024. This decrease was primarily due to cash used in operations. The company also reported a net loss of $13.7 million for the second quarter, compared to a net loss of $21.5 million for the same period in 2024.
Research and development (R&D) expenses decreased by $6.7 million to $9.6 million in the second quarter of 2025, primarily due to the completion and closeout of clinical trials, a decrease in personnel costs, and a decrease in facility-related expenses. General and administrative (G&A) expenses also decreased by $0.6 million to $5.0 million, primarily due to a decrease in non-cash stock-based compensation and personnel-related expenses.
Zetomipzomib, a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis, remains a key focus for Kezar Life Sciences. The company is committed to working closely with the FDA to align on the next trial design for zetomipzomib, which is proposed as a registration-enabling study. The company also announced the promotion of Zung To to Chief Development Officer, who brings 35 years of industry experience to the role.
For more information, visit [Kezar Life Sciences](https://www.kezarlifesciences.com).
References:
[1] https://www.marketscreener.com/news/kezar-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-update-ce7c51d8d889f123
[2] https://seekingalpha.com/news/4484964-kezar-life-sciences-gaap-eps-of-1_87-beats-by-0_42
Kezar Life Sciences reported Q2 GAAP EPS of -$1.87, beating estimates by $0.42. Cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024, primarily due to cash used in operations.
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases, has reported its financial results for the second quarter of 2025. The company's GAAP EPS of -$1.87 beat estimates by $0.42, according to a press release issued on July 2, 2025.The company's cash, cash equivalents, and marketable securities totaled $100.8 million as of June 30, 2025, down from $132.2 million as of December 31, 2024. This decrease was primarily due to cash used in operations. The company also reported a net loss of $13.7 million for the second quarter, compared to a net loss of $21.5 million for the same period in 2024.
Research and development (R&D) expenses decreased by $6.7 million to $9.6 million in the second quarter of 2025, primarily due to the completion and closeout of clinical trials, a decrease in personnel costs, and a decrease in facility-related expenses. General and administrative (G&A) expenses also decreased by $0.6 million to $5.0 million, primarily due to a decrease in non-cash stock-based compensation and personnel-related expenses.
Zetomipzomib, a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis, remains a key focus for Kezar Life Sciences. The company is committed to working closely with the FDA to align on the next trial design for zetomipzomib, which is proposed as a registration-enabling study. The company also announced the promotion of Zung To to Chief Development Officer, who brings 35 years of industry experience to the role.
For more information, visit [Kezar Life Sciences](https://www.kezarlifesciences.com).
References:
[1] https://www.marketscreener.com/news/kezar-life-sciences-reports-second-quarter-2025-financial-results-and-provides-business-update-ce7c51d8d889f123
[2] https://seekingalpha.com/news/4484964-kezar-life-sciences-gaap-eps-of-1_87-beats-by-0_42
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet